Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044

Inclusion Criteria: * Patient is in a stable, monogamous sexual relationship with the same woman for at least 6 months and plans to maintain this relationship for the duration of the study * History of premature ejaculation in the 6 months before study initiation * History of intravaginal ejaculatory latency time (IELT) of \< = 2 minutes in at least half of events * Premature Ejaculation Diagnostic Tool (PEDT) \> =11 * 6 domains of International Index of Erectile Function(IIEF) \>= 21 * Patient and partner must agree to attempt sexual intercourse at minimum intervals specified in the protocol * Patient's partner must have a negative urine pregnancy test at time of screening Exclusion Criteria: * Medical history which affects ADME in the past 3 years * Clinically significant and active disorder in ophthalmic system, gastro-intestine, cardiovascular, respiratory system, endocrine system, autoimmune system or malignant tumor, * Subjects with clinically significant observations considered as unsuitable based on medical judgment in the physical examination and clinical laboratory tests or a medical history * History of psychological disease * Clinically significant allergic disease * Hypersensitivity to TCA, SSRIs(Clomipramine, sertraline, fluoxetine, dapoxetine) * Taken dapoxetine within 3 months * Using other forms of therapy for treatment of PE (behavioral therapy or medications applied to the skin) * Taken another investigational drug within 1 month * History of drug abuse